Engraftment syndrome. Introduction: The local cytokine milieu of target organs is poorly described in acute graft versus host disease (aGVHD) or engraftment syndrome (ES). A novel and noninvasive methodology using D-Squame (Cuderm Dallas, TX) skin sampling discs was utilized to collect the superficial layer of the stratum corneum in patients with acute skin GVHD or ES and cytokines were measured from the keratinocytes which adhered to the disc. Methods: D-squame skin sampling discs were placed on the forearm/wrist of 13 pediatric patients (ages 0.25 years-14 years) for 2 minutes and removed. In patients with acute skin GVHD or ES, samples were obtained from the involved area of the forearm/wrist. This procedure was noted to be painless and safe even for young infants. Superficial keratinocytes were sampled by the fully cured medical grade polyacrylate ester adhesive on the disc. Cytokines were extracted from the sampling discs using a buffer made of phosphate buffered saline and 0.25 molar saline and analyzed using a 38 plex human cytokine Milliplex MAP magnetic bead panel (EMD Millipore Corp, Billerica, MA). Patients were divided into 4 groups; acute skin GVHD (n¼5), isolated engraftment syndrome (n¼2), no acute GVHD or ES (n¼2) and healthy pediatric controls (n¼4). Results: IL1a was elevated in patients with aGVHD as compared to healthy controls and patients who did not develop aGVHD or ES (P ¼ .02 and P ¼ .04) Similarly IL1a was elevated in ES as compared to patients who did not develop aGVHD/ES or to healthy pediatric controls (P ¼.05 and P ¼.01). Conclusions: These preliminary results demonstrate a novel methodology to measure inflammatory cytokines locally in acute skin GVHD and ES. With further patients and analysis, new approaches to management may be indicated in the future.
. Average values of IL1a measured from the epidermis in patients with ES, aGVHD, no ES Introduction: No clear second line agent exists for the treatment of steroid refractory acute graft versus host disease (SR-aGVHD) in children. Alemtuzumab is associated with partial or complete responses in 50-94% of adult patients. Studies are lacking in pediatric patients. The optimal dose for young patients is unknown. Here we present the first phase of a single center dose-escalation study of alemtuzumab for treatment of acute SR-aGVHD in pediatric patients. Methods: Patients were prospectively enrolled at the time of diagnosis of grades II-IV acute GVHD. Patients were initially treated with 4mg/kg/day methylprednisolone. If patients failed to improve within 5 days, or worsened within 48 hours, SR-aGVHD was diagnosed and alemtuzumab was administered at 0.2 mg/kg/day for 5 consecutive days (maximum cumulative dose of 31mg). Additional 0.2mg/kg doses were given on days 15, 22 and 29 (maximum dose 10mg/dose). Patients were monitored weekly for response. Partial response (PR) was defined as improvement in stage of GVHD before 28 days following first alemtuzumab administration, and complete response (CR) was defined as achievement of grade zero GVHD by 28 days following the first alemtuzumab administration. Results: Six patients have been enrolled and 5 patients with grades III (n¼4) or IV (n¼1) GVHD were treated with alemtuzumab so far. Median age was 12 years (range 1.9-27 years). Organs involved included skin (n¼4), gastrointestinal tract (n¼4) and liver (n¼2) ( Table I) . Forty percent of patients (n¼2) had a CR. Sixty percent of patients (n¼3) had a PR. Adverse effects included transient neutropenia or thrombocytopenia (n¼3), fever (n¼2), or asymptomatic EBV viremia (n¼2) and/or adenovirus viremia (n¼2). Conclusion: Alemtuzumab is an active agent for the treatment of SR-a GVHD in pediatric patients. Further dose escalation may increase complete response rates and establish an optimal regimen for successful therapy. III  0  III  I  0  0  0  0  GI  III  III  0  0  0  0  2  Skin  III  III  I  0  0  0  0  0  GI  IV  III  III  III  I  II  Liver  II  II  II  II  II  II  3  Skin  III  III  II  I  0  End of study therapy  GI  III  III  III  4  Skin  IV  IV  II  I  0  End of study therapy  Liver  IV  IV  IV  5  GI  III  0  IV  I  I  I  0  0 Abstracts / Biol Blood Marrow Transplant 19 (2013) S313eS341 S331
